by EpicentRx | Jan 3, 2023 | Blog
To readers of this blog, whoever you are, and however few or many you may be, Happy January 2023. January is named after Janus, the Roman God of beginnings and endings, usually depicted with two faces: one looking forward into the future and one looking backward at...
by EpicentRx | Dec 16, 2022 | Meet The Team
According to Dr. Nacer Abrouk, PhD, a statistician/drug developer that consults part-time for EpicentRx under his company, Clinical Trial Innovations (CTI), “I can’t pump gas, but I can do statistics.” This statement may explain why Nacer, a Porsche enthusiast, owns a...
by EpicentRx | Dec 14, 2022 | 2022, Press Releases
Results from the ROCKET trial, published in the journal Clinical Colorectal Cancer, demonstrate the potential chemoprotective effects of RRx-001 San Diego, Calif., Dec. 14, 2022 – EpicentRx Inc. (“EpicentRx”), a leading-edge, clinical stage biopharmaceutical...
by EpicentRx | Dec 13, 2022 | Blog
San Antonio is home to the Alamo where in 1836, according to the mythic story, a handful of outgunned and outmanned Texans made a final last stand against a besieging Mexican army during the Texas War for Independence. In 2022, almost two centuries after the Battle of...
by EpicentRx | Dec 8, 2022 | Blog
The 2022 Inflammasome Summit is in the books—well, more accurately, in the notebooks of the in-person attendees who took copious notes. TBH, we haven’t witnessed scribbling like that since freshman history class. Which makes sense because as first in-person...
